ERCC1 and cervical squamous cell carcinoma: (28) demonstrated that advanced cervical squamous cell carcinoma patients with low ERCC1 mRNA expression had a significantly higher rate of complete response to cisplatin-based concurrent chemoradiotherapy (86.21%) than those with a high level of ERCC1 (19.36%, P < 0.001).